XENE Xenon Pharmaceuticals Inc.
Nasdaq · SEC CIK 1582313 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $22.97M 14 sales by 6 insiders
- Filings on record
- 116 since 2021-08-25, latest 2026-09-03 20:26
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| MORTIMER IAN | Pres, CEO, INTERIM CFO, Dir | — | $21.30M |
| KENNEY CHRISTOPHER JOHN | Chief Medical Off | — | $670.3K |
| GANNON STEVEN | Dir | — | $640.6K |
| DiFabio Andrea | CLO | — | $230.8K |
| PATOU GARY | Dir | — | $70.3K |
| Cannon Gillian | Dir | — | $63.2K |
| GAROFALO ELIZABETH A. | Dir | — | — |
| Gover Justin D. | Dir | — | — |
| Svoronos Dawn | Dir | — | — |
| Machado Patrick | Dir | — | — |
Transactions 97
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-03 20:26 | 2026-09-01 | XENE | Svoronos Dawn | Dir | M - OptEx | $8.15 | +5,144 | 31.4K | +20% | +$41.9K |
| MT | 2026-08-31 21:59 | 2026-08-28 | XENE | KENNEY CHRISTOPHER JOHN | Chief Medical Off | S - Sale | $60.25 | -7,068 | 2 | -100% | -$425.8K |
| 2026-08-13 16:33 | 2026-08-11 | XENE | GANNON STEVEN | Dir | S - Sale | $64.06 | -10.0K | 1,870 | -84% | -$640.6K | |
| T | 2026-06-08 21:19 | 2026-06-05 | XENE | PATOU GARY | Dir | S - Sale | $53.14 | -1,322 | 24.9K | -5% | -$70.3K |
| T | 2026-06-08 21:19 | 2026-06-05 | XENE | Cannon Gillian | Dir | S - Sale | $53.14 | -1,190 | 1,455 | -45% | -$63.2K |
| D | 2026-06-03 21:04 | 2026-06-01 | XENE | PATOU GARY | Dir | M - OptEx | — | +2,645 | 26.2K | +11% | — |
| D | 2026-06-03 21:04 | 2026-06-01 | XENE | Machado Patrick | Dir | M - OptEx | — | +2,645 | 2,645 | New | — |
| D | 2026-06-03 21:04 | 2026-06-01 | XENE | Gover Justin D. | Dir | M - OptEx | — | +2,645 | 2,645 | New | — |
| D | 2026-06-03 21:04 | 2026-06-01 | XENE | GAROFALO ELIZABETH A. | Dir | M - OptEx | — | +2,645 | 2,645 | New | — |
| D | 2026-06-03 21:04 | 2026-06-01 | XENE | GANNON STEVEN | Dir | M - OptEx | — | +2,645 | 13.3K | +25% | — |
| D | 2026-06-03 21:04 | 2026-06-01 | XENE | GANNON STEVEN | Dir | F - Tax | $53.41 | -1,416 | 11.9K | -11% | -$75.6K |
| D | 2026-06-03 21:03 | 2026-06-01 | XENE | Cannon Gillian | Dir | M - OptEx | — | +2,645 | 2,645 | New | — |
| D | 2026-06-03 21:03 | 2026-06-01 | XENE | Svoronos Dawn | Dir | M - OptEx | — | +2,645 | 27.6K | +11% | — |
| D | 2026-06-03 21:03 | 2026-06-01 | XENE | Svoronos Dawn | Dir | F - Tax | $53.41 | -1,416 | 26.2K | -5% | -$75.6K |
| D | 2026-05-13 21:40 | 2026-05-12 | XENE | GANNON STEVEN | Dir | M - OptEx | $7.38 | +3,500 | 10.6K | +49% | +$25.8K |
| DT | 2026-03-13 | 2026-03-12 | XENE | DiFabio Andrea | CLO | M - OptEx | — | +3,750 | 8,643 | +77% | — |
| DT | 2026-03-13 | 2026-03-13 | XENE | DiFabio Andrea | CLO | S - Sale+OE | $55.23 | -1,342 | 7,301 | -16% | -$74.1K |
| DT | 2026-03-13 | 2026-03-12 | XENE | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | — | +12.5K | 27.2K | +85% | — |
| DT | 2026-03-13 | 2026-03-13 | XENE | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $55.23 | -7,308 | 19.9K | -27% | -$403.6K |
| DT | 2026-03-13 | 2026-03-12 | XENE | KENNEY CHRISTOPHER JOHN | Chief Medical Off | M - OptEx | — | +3,750 | 8,479 | +79% | — |
| DT | 2026-03-13 | 2026-03-13 | XENE | KENNEY CHRISTOPHER JOHN | Chief Medical Off | S - Sale+OE | $55.23 | -1,410 | 7,069 | -17% | -$77.9K |
| DMT | 2026-03-11 | 2026-03-09 | XENE | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | $6.74 | +290.0K | 26.0K | New | +$1.95M |
| DMT | 2026-03-11 | 2026-03-09+ | XENE | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $60.32 | -281.3K | 14.7K | -95% | -$16.97M |
| DT | 2026-03-11 | 2026-03-09 | XENE | DiFabio Andrea | CLO | M - OptEx | — | +7,500 | 7,500 | New | — |
| DT | 2026-03-11 | 2026-03-10 | XENE | DiFabio Andrea | CLO | S - Sale+OE | $60.11 | -2,607 | 4,893 | -35% | -$156.7K |
| DT | 2026-03-11 | 2026-03-09 | XENE | KENNEY CHRISTOPHER JOHN | Chief Medical Off | M - OptEx | — | +7,500 | 7,500 | New | — |
| DT | 2026-03-11 | 2026-03-10 | XENE | KENNEY CHRISTOPHER JOHN | Chief Medical Off | S - Sale+OE | $60.11 | -2,771 | 4,729 | -37% | -$166.6K |
| DMT | 2026-01-02 | 2026-01-02 | XENE | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $44.43 | -40.0K | 6,000 | -87% | -$1.78M |
| DT | 2026-01-02 | 2026-01-02 | XENE | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | $7.49 | +40.0K | 46.0K | +667% | +$299.6K |
| MT | 2025-12-09 | 2025-12-05+ | XENE | MORTIMER IAN | Pres, CEO, Dir | S - Sale | $45.33 | -25.2K | 16.8K | -60% | -$1.14M |
| T | 2025-12-03 | 2025-11-28 | XENE | MORTIMER IAN | Pres, CEO, Dir | S - Sale | $45.01 | -97 | 31.2K | -0.3% | -$4,366 |
| DT | 2025-10-01 | 2025-10-01 | XENE | MORTIMER IAN | Pres, CEO, INTERIM CFO, Dir | S - Sale+OE | $40.16 | -25.0K | 31.3K | -44% | -$1.00M |
| DT | 2025-10-01 | 2025-10-01 | XENE | MORTIMER IAN | Pres, CEO, INTERIM CFO, Dir | M - OptEx | $7.69 | +25.0K | 56.3K | +80% | +$192.2K |
| D | 2025-06-06 | 2025-06-05 | XENE | GANNON STEVEN | Dir | S - Sale | $30.48 | -3 | 7,141 | -0.0% | -$91.44 |
| D | 2025-05-16 | 2025-05-14 | XENE | GANNON STEVEN | Dir | M - OptEx | $12.57 | +5,144 | 7,144 | +257% | +$64.7K |
| DMT | 2025-01-27 | 2025-01-23+ | XENE | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | $17.76 | +55.0K | 46.5K | New | +$976.8K |
| DMT | 2025-01-27 | 2025-01-23+ | XENE | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $40.25 | -55.0K | 31.3K | -64% | -$2.21M |
| DM | 2024-12-19 | 2024-12-18 | XENE | AULIN SHERRY | CFO | F - Tax | $41.28 | -6,625 | 11.5K | -37% | -$273.5K |
| DM | 2024-12-19 | 2024-12-18 | XENE | AULIN SHERRY | CFO | M - OptEx | $10.79 | +25.3K | 9,334 | New | +$273.4K |
| DM | 2024-12-19 | 2024-12-18 | XENE | AULIN SHERRY | CFO | S - Sale+OE | $41.21 | -18.7K | 0 | -100% | -$770.9K |
| DM | 2024-11-22 | 2024-11-22 | XENE | PATOU GARY | Dir | M - OptEx | $10.24 | +6,586 | 26.7K | +33% | +$67.4K |
| DM | 2024-11-22 | 2024-11-22 | XENE | PATOU GARY | Dir | F - Tax | $39.80 | -1,695 | 25.6K | -6% | -$67.5K |
| DM | 2024-11-22 | 2024-11-22 | XENE | PATOU GARY | Dir | S - Sale+OE | $41.08 | -4,891 | 23.6K | -17% | -$200.9K |
| D | 2024-03-11 | 2024-03-08 | XENE | GAROFALO ELIZABETH A. | Dir | M - OptEx | $18.56 | +3,500 | 3,500 | New | +$65.0K |
| D | 2024-03-11 | 2024-03-08 | XENE | GAROFALO ELIZABETH A. | Dir | S - Sale+OE | $45.69 | -2,092 | 0 | -100% | -$95.6K |
| D | 2024-03-11 | 2024-03-08 | XENE | GAROFALO ELIZABETH A. | Dir | F - Tax | $46.16 | -1,408 | 2,092 | -40% | -$65.0K |
| M | 2024-03-08 | 2024-03-07 | XENE | GANNON STEVEN | Dir | S - Sale | $46.28 | -13.0K | 14.0K | -48% | -$601.6K |
| DM | 2024-03-08 | 2024-03-07 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | M - OptEx | $9.85 | +8,641 | 9,632 | +872% | +$85.1K |
| DM | 2024-03-08 | 2024-03-07 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | S - Sale+OE | $46.28 | -7,137 | 14.5K | -33% | -$330.3K |
| DM | 2024-03-08 | 2024-03-07 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | F - Tax | $45.96 | -1,504 | 15.5K | -9% | -$69.1K |
| 2024-01-02 | 2023-12-29 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | J - Other | $0.00 | -8,398 | 8,398 | -50% | $0 | |
| DM | 2023-12-20 | 2023-12-19 | XENE | AZAB MOHAMMAD | Dir | M - OptEx | $9.85 | +4,320 | 74.2K | +6% | +$42.6K |
| AI | 2023-12-15 | 2023-12-14 | XENE | PATOU GARY | Dir | S - Sale | $41.05 | -7,598 | 4,902 | -61% | -$311.9K |
| DM | 2023-12-15 | 2023-12-13 | XENE | PATOU GARY | Dir | S - Sale+OE | $39.29 | -11.4K | 23.6K | -33% | -$447.1K |
| DM | 2023-12-15 | 2023-12-13 | XENE | PATOU GARY | Dir | M - OptEx | $9.55 | +14.4K | 30.0K | +93% | +$137.5K |
| DM | 2023-12-15 | 2023-12-13 | XENE | PATOU GARY | Dir | F - Tax | $39.68 | -3,022 | 28.7K | -10% | -$119.9K |
| DI | 2023-12-15 | 2023-12-13 | XENE | PATOU GARY | Dir | S - Sale+OE | $41.05 | -7,598 | 4,902 | -61% | -$311.9K |
| 2023-08-24 | 2023-08-24 | XENE | Svoronos Dawn | Dir | S - Sale | $38.70 | -25.0K | 25.0K | -50% | -$967.5K | |
| DM | 2023-06-01 | 2023-05-30+ | XENE | PIMSTONE SIMON N. | Dir | S - Sale+OE | $38.90 | -131.2K | 37.0K | -78% | -$5.10M |
| DM | 2023-06-01 | 2023-05-31+ | XENE | PIMSTONE SIMON N. | Dir | M - OptEx | $15.30 | +134.2K | 51.0K | New | +$2.05M |
| DM | 2023-06-01 | 2023-05-31+ | XENE | PIMSTONE SIMON N. | Dir | F - Tax | $38.44 | -51.9K | 30.3K | -63% | -$2.00M |
| DM | 2023-05-26 | 2023-05-24 | XENE | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $41.41 | -31.7K | 31.3K | -50% | -$1.31M |
| DM | 2023-05-26 | 2023-05-24 | XENE | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | $9.60 | +69.3K | 48.6K | New | +$665.5K |
| DM | 2023-05-26 | 2023-05-24 | XENE | MORTIMER IAN | Pres, CEO, Dir | F - Tax | $41.84 | -12.4K | 40.9K | -23% | -$518.1K |
| 2023-03-24 | 2023-03-24 | XENE | KENNEY CHRISTOPHER JOHN | Chief Medical Off | S - Sale | $35.01 | -700 | 0 | -100% | -$24.5K | |
| DM | 2023-03-09 | 2023-03-07 | XENE | PIMSTONE SIMON N. | Dir | F - Tax | $37.13 | -3,778 | 63.2K | -6% | -$140.3K |
| DM | 2023-03-09 | 2023-03-07 | XENE | PIMSTONE SIMON N. | Dir | S - Sale+OE | $36.98 | -19.2K | 34.0K | -36% | -$711.2K |
| DM | 2023-03-09 | 2023-03-07 | XENE | PIMSTONE SIMON N. | Dir | M - OptEx | $2.64 | +72.0K | 47.2K | New | +$190.2K |
| D | 2022-12-13 | 2022-12-12 | XENE | AZAB MOHAMMAD | Dir | M - OptEx | $2.68 | +3,086 | 69.9K | +5% | +$8,270 |
| DM | 2022-11-28 | 2022-11-23+ | XENE | PATOU GARY | Dir | S - Sale+OE | $34.55 | -3,994 | 23.6K | -14% | -$138.0K |
| D | 2022-11-28 | 2022-11-25 | XENE | PATOU GARY | Dir | F - Tax | $34.37 | -120 | 25.5K | -0.5% | -$4,124 |
| D | 2022-11-28 | 2022-11-25 | XENE | PATOU GARY | Dir | M - OptEx | $2.68 | +2,057 | 25.6K | +9% | +$5,513 |
| DM | 2022-09-07 | 2022-09-02 | XENE | AULIN SHERRY | CFO | M - OptEx | $6.97 | +18.6K | 9,032 | New | +$130.1K |
| D | 2022-09-07 | 2022-09-02 | XENE | AULIN SHERRY | CFO | F - Tax | $39.53 | -3,293 | 15.4K | -18% | -$130.2K |
| D | 2022-09-07 | 2022-09-02 | XENE | AULIN SHERRY | CFO | S - Sale+OE | $39.57 | -15.4K | 0 | -100% | -$607.6K |
| DM | 2022-09-02 | 2022-08-31+ | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | M - OptEx | $4.25 | +72.5K | 34.7K | New | +$307.9K |
| DM | 2022-09-02 | 2022-08-31+ | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | F - Tax | $38.62 | -7,693 | 60.7K | -11% | -$297.1K |
| DM | 2022-09-02 | 2022-08-31+ | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | S - Sale+OE | $38.31 | -65.2K | 25.6K | -72% | -$2.50M |
| DM | 2022-08-16 | 2022-08-12 | XENE | EMPFIELD JAMES R. | EVP, Drug Discovery | M - OptEx | $4.24 | +65.0K | 75.0K | +650% | +$275.8K |
| DM | 2022-08-16 | 2022-08-12 | XENE | EMPFIELD JAMES R. | EVP, Drug Discovery | S - Sale+OE | $38.31 | -57.7K | 31.9K | -64% | -$2.21M |
| D | 2022-08-16 | 2022-08-12 | XENE | EMPFIELD JAMES R. | EVP, Drug Discovery | F - Tax | $38.02 | -7,257 | 67.7K | -10% | -$275.9K |
| M | 2022-08-16 | 2022-08-12+ | XENE | PIMSTONE SIMON N. | Dir | S - Sale | $38.25 | -177.1K | 92.0K | -66% | -$6.78M |
| A | 2022-03-08 | 2022-03-08 | XENE | PIMSTONE SIMON N. | Dir | S - Sale | $30.80 | -2,500 | 193.1K | -1% | -$77.0K |
| DM | 2022-03-08 | 2022-03-04 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | M - OptEx | $3.67 | +7,406 | 38.9K | +23% | +$27.2K |
| D | 2022-03-08 | 2022-03-04 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | F - Tax | $31.42 | -696 | 32.8K | -2% | -$21.9K |
| DM | 2022-03-08 | 2022-03-04 | XENE | ROBIN SHERRINGTON | EVP, Strategy, Innovation | S - Sale+OE | $30.50 | -21.7K | 32.2K | -40% | -$662.2K |
| DM | 2022-03-08 | 2022-03-04+ | XENE | EMPFIELD JAMES R. | EVP, Drug Discovery | M - OptEx | $7.43 | +67.5K | 51.8K | New | +$501.4K |
| DM | 2022-03-08 | 2022-03-04+ | XENE | EMPFIELD JAMES R. | EVP, Drug Discovery | F - Tax | $30.72 | -16.3K | 42.9K | -28% | -$501.7K |
| DM | 2022-03-08 | 2022-03-04+ | XENE | EMPFIELD JAMES R. | EVP, Drug Discovery | S - Sale+OE | $30.63 | -51.2K | 10.0K | -84% | -$1.57M |
| DM | 2022-03-08 | 2022-03-04+ | XENE | PIMSTONE SIMON N. | Dir | M - OptEx | $3.67 | +30.9K | 230.8K | +15% | +$113.3K |
| DM | 2022-03-08 | 2022-03-04+ | XENE | PIMSTONE SIMON N. | Dir | S - Sale+OE | $29.28 | -55.0K | 185.6K | -23% | -$1.61M |
| DM | 2022-03-08 | 2022-03-04+ | XENE | PIMSTONE SIMON N. | Dir | F - Tax | $30.62 | -2,953 | 219.5K | -1% | -$90.4K |
| 2022-01-21 | 2022-01-21 | XENE | KENNEY CHRISTOPHER JOHN | Chief Medical Off | P - Purchase | $28.81 | +700 | 700 | New | +$20.2K | |
| D | 2021-12-17 | 2021-12-15 | XENE | AZAB MOHAMMAD | Dir | M - OptEx | $3.67 | +3,086 | 66.8K | +5% | +$11.3K |
| D | 2021-12-10 | 2021-12-08 | XENE | PATOU GARY | Dir | M - OptEx | $3.67 | +2,057 | 25.6K | +9% | +$7,549 |
| 2021-12-07 | 2021-12-06 | XENE | Von Seggern Christopher | Chief Commercial Off | P - Purchase | $24.40 | +4,000 | 4,000 | New | +$97.6K | |
| 2021-11-16 | 2021-11-15 | XENE | PIMSTONE SIMON N. | Dir | S - Sale | $31.33 | -17.6K | 210.2K | -8% | -$550.1K |
Purchase Sale Sale after option exercise All abbreviations